445305-88-4

Upstream product

• 681807-60-3 (1R,2S)-ethyl 1-amino-2-vinylcyclopropanecarboxylate hydrochloride 
• 259214-37-4 (2S,4R)-1-(tert-butoxycarbonyl)-4-(7-methoxy-2-phenylquinolin-4-yloxy)pyrrolidine-2-carboxylic acid 
• 259214-54-5 (trans)-ethyl 1-amino-2-vinylcyclopropanecarboxylate hydrochloride 

Relevant academic research and scientific papers

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C virus inhibitors

The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which inhibit the function of the NS3 protease (also referred to herein as “serine protease”) encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS3 protease.

Substituted cycloalkyl P1' hepatitis C virus inhibitors

The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.